MANNKIND CORP Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MANNKIND CORP stock issued during period, value, conversion of convertible securities for the quarter ending 2026-03-31 was $1.74M.
- MANNKIND CORP stock issued during period, value, conversion of convertible securities for fiscal 2019 was $4.58M.
- MANNKIND CORP stock issued during period, value, conversion of convertible securities for fiscal 2017 was $21.10M.
- MANNKIND CORP stock issued during period, value, conversion of convertible securities for fiscal 2015 was $7.93M.
- MANNKIND CORP stock issued during period, value, conversion of convertible securities for fiscal 2012 was $184.54M, a 1560.10% increase from fiscal 2011.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2026-03-31 | $1.74M 10-Q · filed 2026-08-05 | |
| 2019-12-31 | $4.58M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $21.10M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $7.93M 10-K · filed 2018-02-27 | |
| 2012-12-31 | $184.54M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $11.12M 10-K · filed 2014-03-03 | |
| 2010-12-31 | $16.68M 10-K · filed 2014-03-03 | |
| 2004-12-31 | $18.15M 10-K · filed 2014-03-03 | |
| 2000-12-31 | $1.07M 10-K · filed 2014-03-03 | |
| 1999-12-31 | $995.00K 10-K · filed 2014-03-03 | |
| 1998-12-31 | $1.20M 10-K · filed 2014-03-03 | |
| 1997-12-31 | $60.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |